Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Vaccines news

Show

From To
HIV immunity: rare gene differences offer hope for treatment

Seven years after the ‘Berlin patient’ was cured of HIV, scientists are looking to natural immunity through genetic variation to create vaccine and gene therapies

Published
12 May 2015
From
The Guardian
Does Llama Blood Hold the Key to an HIV Vaccine?

Previous research suggested that llamas given an experimental HIV vaccine produce virus-fighting antibodies that are smaller than those produced by humans. As a result, these smaller antibodies do a better job of latching onto the receptors in human cells where part of the virus lives. An HIV vaccine should target these receptors.

Published
11 May 2015
From
Healthline
Improving the effect of HIV drugs by the use of a vaccine

A vaccine containing a protein necessary for virus replication can boost an HIV-infected patient's immune system, according to clinical research published in the open-access journal Retrovirology. This boost can result in increased effectiveness of antiretroviral drugs.

Published
29 April 2015
From
Eurekalert Inf Dis
An HIV Cure and a Vaccine within the Next 15 Years?

Earlier this year, Bill Gates caused a ripple in the media by expressing optimism that a vaccine and a cure for HIV will become a reality within the next 15 years. From TAG’s perspective, Gates’s buoyancy does have some scientific basis—there have been encouraging signs of progress on both the vaccine and cure fronts in recent years—but the challenges that lie ahead must not be underestimated.

Published
13 April 2015
From
Treatment Action Group
Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial

There is now intense interest in learning whether the blossoming array of broadly neutralizing antibodies (bNAbs) can be put to therapeutic and preventive use. A paper published yesterday in Nature describes encouraging results from a phase I trial involving the bNAb 3BNC117. Reflecting the level of interest in the topic, the paper has attracted extensive press coverage.

Published
10 April 2015
From
TAG
In first human study, new antibody therapy shows promise in suppressing HIV infection

The new study, conducted in Michel Nussenzweig’s Laboratory of Molecular Immunology, finds that administration of a potent antibody, called 3BNC117, can catch HIV off guard and reduce viral loads.

Published
09 April 2015
From
Rockefeller University press release
We’re in a renaissance period for the HIV vaccine

Wayne Koff, chief scientific officer at the International AIDS Vaccine Initiative (IAVI), spoke in an interview about the challenges in developing a vaccine for one of the trickiest and deadliest known viruses, how scientists are getting closer to developing a vaccine for human immunodeficiency virus (HIV), and what makes India attractive for vaccine development.

Published
01 April 2015
From
Hindustan Times
Immune Response BioPharma, Inc Announces the FDA has Accepted REMUNE HIV/AIDS Vaccine BLA for Review

Immune Response BioPharma, Inc., Today provides an update on REMUNE and announces the FDA has accepted the REMUNE HIV/AIDS vaccine BLA (biologics licensing application) for review for therapeutic treatment in adults with HIV/AIDS.

Published
31 March 2015
From
Immune Response BioPharma press release
University of RochesterTests HIV Vaccine Pill

Researchers at the University of Rochester Medical Center are testing a new oral vaccine to prevent infection with HIV, the virus that causes AIDS. The vaccine is unique because it is given as a pill, unlike most HIV vaccines tested to date that have been given as shots.

Published
20 February 2015
From
University of Rochester press release
NIH-sponsored HIV vaccine trial launches in South Africa

A clinical trial has launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in volunteers. This experimental regimen is based on the one tested in the RV144 trial - -the first to demonstrate that a vaccine can protect people from HIV infection -- but is designed to potentially provide greater protection and is adapted to the predominant HIV subtype in southern Africa.

Published
19 February 2015
From
Eurekalert Medicine & Health
← First12345...20Next →

Filter by country